Assembly Biosciences Inc ASMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $22.74
- Day Range
- $21.80–22.92
- 52-Week Range
- $21.80–39.71
- Bid/Ask
- $22.10 / $22.60
- Shares Outstanding
- 20.36M
- Market Cap
- $451.60M
- Volume/Avg
- 349,444 / 274,262
Key Statistics
- Price/Earnings (Normalized)
- 15.33
- Price/Sales
- 4.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 73
- Website
- https://www.assemblybio.com
Valuation
|
Metric
|
ASMB
|
|---|---|
Price/Earnings (Normalized) | 15.33 |
Price/Book Value | 1.44 |
Price/Sales | 4.85 |
Price/Cash Flow | 80.07 |
Price/Earnings
ASMB
Financial Strength
|
Metric
|
ASMB
|
|---|---|
Quick Ratio | 13.70 |
Current Ratio | 13.99 |
Interest Coverage | — |
Quick Ratio
ASMB
Profitability
|
Metric
|
ASMB
|
|---|---|
Return on Assets (Normalized) | 2.89% |
Return on Equity (Normalized) | 3.63% |
Return on Invested Capital (Normalized) | −1.15% |
Return on Assets
ASMB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!M@$s! | LOCK|mNmy# | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?t>g?&s | LOCK|xLBgX | $76B | |||
| Moderna Inc
MRNA
| LOCK|#m>YvZ | LOCK|Bs | $75B | |||
| argenx SE ADR
ARGX
| LOCK|&!%rBL | LOCK|&>p | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Cc>#R< | LOCK|%^# | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&J^!^GF | LOCK|x!^@^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#!^!@Y&^ | LOCK|w<&z | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!>&Tv< | LOCK|j$Y | $24B | |||
| Incyte Corp
INCY
| LOCK|>^T@$% | LOCK|Rp | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|DN<^m%> | LOCK|k>S | $15B |
United States